Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows

Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows
In men suspected of recurring prostate cancer, imaging with Axumin (18F-fluciclovine) was able to accurately reveal sites of recurrence, which led to a change of treatment plans for 59 percent of the patients, topline results from the Phase 3 LOCATE trial show. Trial findings were recently presented in a poster, “Impact of positron emission tomography with 18F-fluciclovine on management of patients with suspected recurrence of prostate cancer: results from the LOCATE trial,” at the American Urological Association Annual Meeting (AUA 2018), in San Francisco. “We are very pleased to share these LOCATE study topline results with the prestigious urology community at AUA 2018,” Jonathan Allis, CEO of Blue Earth Diagnostics, which conducted the study, said in a press release. “As part of our mission to develop and commercialize innovative PET imaging agents for cancer, Blue Earth Diagnostics conducted the LOCATE study in the United States to evaluate the utility of 18F fluciclovine PET/CT in providing physicians with actionable information for the management of men with recurrent prostate cancer. We plan to publish the results from the LOCATE trial in an upcoming peer-reviewed publication,” he said. Axumin, a fluciclovine F 18 injection, is an imaging agent for positron emission tomography (PET) and c
Subscribe or to access all post and page content.

Tagged , , , , .

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that make up the lining of blood vessels — found in the umbilical cord of newborns.

Leave a Comment

Your email address will not be published. Required fields are marked *